AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05368987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear Conditioning and Extinction Paradigm
Description: Participants will undergo a 3-day experimental paradigm. On day 1, participants will undergo a resting-state and structural scans in the fMRI scanner. The data from this scan will be used to determine the specific location of the TMS target for each participant. And participants will be aversively conditioned to two cues in the fMRI scanner. Task based and resting-state scans will occur on this day.~On day 2, subjects will undergo extinction training outside of the scanner where one of the conditioned cues will be paired with TMS in a temporally and anatomically specific manner. A resting-state scan will occur before and after inside the scanner.~On day 3, conditioned cues will be presented during the extinction recall phase of the study. This phase will be conducted in the fMRI scanner. Task-based and resting-state scans will occur on this day.
Study NCT06031623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBOA
Description: Resuscitative endovascular balloon occlusion of the aorta (REBOA)is a device composed of a catheter attached to an inflatable balloon. It is inserted through the common femoral artery and guided to the thoracic aorta.
Study NCT06308341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality technique + Motor Imagery technique + Routine Physical Therapy
Description: Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min
Study NCT06308341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality + Routine Physical Therapy
Description: Routine physical therapy protocol will be given for 30 minutes along with cycling and walking for 10-15 minutes.~VR techniques for 10-15 minutes The first eight weeks focus on simple activities to enhance balance and motor function, such as tennis, boxing, bowling, kicking, soccer, table tilt, penguin slide, tilt city, single-leg extension, and torso twist. Exercise difficulty is adjusted based on performance, gradually progressing from easier to more challenging activities.
Study NCT06308341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery +Routine Physical Therapy
Description: Routine physical therapy protocol will be given for 30 minutes along with Cycling and walking for 10-15 minutes MI techniques for 10-15 minutes The motor imagery program me will be performed in three steps; STEP I: The patients will watch the videos recorded by the examiner. STEP II: The patients will be asked to close their eyes, focus, and imagine how they are doing the task they had previously observed ten times.~Step III: The patient will be asked to attempt the activity with his affected limbs according to the verbal command of the examiner Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min.
Study NCT05725005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN51
Description: ASN51 formulation for oral capsule
Study NCT05820568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT-IU
Description: Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry
Study NCT03692754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: Atorvastatin will be given in 20 mg po qn for 1 month
Study NCT03692754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin will be given in 10 mg po qn for 1 month
Study NCT03692754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be given in 40mg po qd for 4 days
Study NCT03692754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given in 40mg po qd for 4 days
Study NCT05154006 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information about benefits of the behavior
Description: The women will be informed that the safe carrying behaviors can reduce pelvic strain. She is informed about the benefits reducing pelvic strain may imply \[5.1; 5.3.,5.6 Information about health; environmental; social; and emotional consequences, (Michie et al., 2013)\]
Study NCT05154006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information about benefits of the behavior
Description: The women will be informed that the safe carrying behaviors can reduce pelvic strain. She is informed about the benefits reducing pelvic strain may imply \[5.1; 5.3.,5.6 Information about health; environmental; social; and emotional consequences, (Michie et al., 2013)\]
Study NCT05154006 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instruction on how to perform a behavior
Description: For the target behavior reduce carried weight information on recommended weight limits will be given. The women will be encouraged, that even if these limits may not be feasible for them, any reduction of weight can still reduce the strain on the pelvic floor.~For the target behavior safe lifting techniques, instructions to learn the correct behavior (how to perform safe lifting techniques?) based on leaflets developed and validated by Caagbay et al., (2017, 2020) \[4.1 Instruction on how to perform a behavior (Michie et al., 2013)\]
Study NCT05154006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instruction on how to perform a behavior
Description: For the target behavior reduce carried weight information on recommended weight limits will be given. The women will be encouraged, that even if these limits may not be feasible for them, any reduction of weight can still reduce the strain on the pelvic floor.~For the target behavior safe lifting techniques, instructions to learn the correct behavior (how to perform safe lifting techniques?) based on leaflets developed and validated by Caagbay et al., (2017, 2020) \[4.1 Instruction on how to perform a behavior (Michie et al., 2013)\]
Study NCT05154006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Description: Self-efficacy will be promoted by the four sources of self-efficacy (Bandura, 1977): 1) Mastery Experiences (experience that one is able to successfully apply the behavior), vicarious experience (observing successful others performing the safe carrying behavior), verbal persuasion (receiving positive feedback when performing the behavior and encouraging messages to do so) and emotional state (e.g. being in a positive emotional state when performing the behavior). \[6.1 Demonstration of the behavior; 8.1 Behavioral practice/rehearsal; 15.1 Verbal persuasion about capability; 15.2 Mental rehearsal of successful performance; 15.3 Focus on past success;15.4 Self-talk; 5.4 Monitoring of emotional consequences (Michie et al., 2013)\]
Study NCT05154006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: A self-selected social partner from the same or neighboring household (e.g. husband, mother-in-law) will be involved in the learning process (observational learning, feedback). The partner will participate in the intervention activities and will be instructed to provide emotional social support and practical informational support. \[3.2 practical support, 3.3 emotional support; 6.3 Information about others' approval (Michie et al., 2013).\]
Study NCT04225611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The investigators have developed a topically-applied corticosteroid-delivery system that has the potential to treat recurrent cystoid macular edema with fewer risks to patient, and more dose control. The system is comprised of a drug-polymer film that is completely encapsulated within the periphery of a hydrogel that is commonly used to make contact lenses.
Study NCT05593250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905
Description: subcutaneous
Study NCT05593250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous ,placebo
Study NCT05677113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBECO
Description: QBECO is a site specific immunomodulator (SSI) designed to promote innate immune responses in the gastrointestinal tract and related organs, including the liver. QBECO will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
Study NCT05677113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prepared in the same way as the IP. Placebo will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
Study NCT06258330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM003
Description: Bispecific Personalized Aptamer for intratumoral administration
Study NCT05135897 — intervention group
Intervention type: DEVICE
Intervention: Electroconvulsive therapy
Description: Treatment with Electroconvulsive therapy
Study NCT05135897 — intervention group
Intervention type: DEVICE
Intervention: rTMS
Description: repetitive Transcranial Magnetic Stimulation
Study NCT05642442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule(s) administered every day (QD) orally. Titration may proceed at a rate of 1 matching placebo capsule per day every 7 days as required for optimal efficacy and tolerability up to a maximum number of 3 matching placebo capsules per day.
Study NCT05642442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvecaltamide
Description: Suvecaltamide capsule administered every day (QD) orally. Titration may proceed at a rate of 10 mg suvecaltamide per day every 7 days as required for optimal efficacy and tolerability up to a maximum dose of 30 mg suvecaltamide per day.
Study NCT05384106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: (R)-1,3-butanediol
Description: Avela™ (R)-1,3-butanediol is intended to induce ketosis in the general adult population. Avela™ (R)-1,3-butanediol is GRAS for use in beverages, bars, and gels
Study NCT06162559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib 300mg is taken orally twice daily
Study NCT06162559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle
Study NCT06162559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle
Study NCT05134285 — intervention group
Intervention type: OTHER
Intervention: blood pressure,BMI, blood sample
Description: Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.
Study NCT04883294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electronic Nose
Description: All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. Failed breath tests were excluded from analysis; the reason for failure was documented.
Study NCT05579951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient specific instrumentation
Description: Total knee replacement with patient specific instrumentation
Study NCT05579951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Total knee replacement with conventional instrumentation
Study NCT05579951 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient specific instrumentation
Description: Medacta GMK Sphere MyKnee Patient specific Instrumentation
Study NCT05401578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canakinumab
Description: Canakinumab (Ilaris®, Novartis Switzerland) will be used in the recommended standard dose of 150 mg subcutaneously once. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
Study NCT05401578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% NaCl)
Description: 1 ml 0.9 % saline solution s.c. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
Study NCT06534060 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Genetic: MB-105
Description: MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.
Study NCT05814653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment-Primary Care
Description: Novel treatment that borrows key intervention strategies from standard family-based treatment. It uses trained primary care providers (PCPs), in consultation with a mental health provider, to deliver family-based treatment strategies in community-based clinics to increase caregiver self-efficacy to reverse their child's dietary restriction and weight loss.
Study NCT05814653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Based Treatment
Description: Delivered by a mental health provider in a traditional mental health or eating disorder specialty setting. First-line evidence-based treatment for adolescent eating disorders that targets caregiver self-efficacy as a mechanism to facilitate weight restoration and ultimately symptom remission in adolescents.
Study NCT06081452 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: Members of the public will be asked to complete a survey that collects information on individuals perception of health and disease and their views on breath testing.
Study NCT05808257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fibre Laser
Description: The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
Study NCT05808257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium:Yttrium-Aluminum-Garnet
Description: The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
Study NCT05627245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV
Study NCT05627245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05627245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05627245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05627245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Pharmacokinetic study
Study NCT05627245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET-CT
Study NCT05627245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study NCT05823220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homeless diversion (HD)
Description: Participants will receive services from specialty-trained community health workers and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
Study NCT05823220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual (TAU)
Description: Participants will receive a list of community resources they can contact to receive services and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
Study NCT05962398 — intervention group
Intervention type: GENETIC
Intervention: AAV5-hFIXco-Padua
Description: Single intravenous infusion of AAV5-hFIXco-Padua in the study CSL222_2001 (NCT03489291) or CSL222_3001 (NCT03569891).
Study NCT06016387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib 150 MG
Description: Tucatinib is a potent, selective, adenosine triphosphate-competitive small-molecule inhibitor of the receptor tyrosine kinase HER2. The molecular formula for tubatinib is C26H24N8O2 and it has a molecular weight of 480.52 g/mol.
Study NCT06016387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: MYL-1401O contains the active substance trastuzumab, which is an IgG1 monoclonal antibody. The molecular size of the intact molecule is around 148 kDa.~Each vial of MYL-1401O contains 150 mg of lyophilized proposed active biosimilar substance trastuzumab as well as 3.36 mg L-Histidine Hydrochloride, 2.16 mg L-Histidine, 115.2 mg sorbitol and 33.6 mg PEG-3350 (Macrogol 3350). Sorbitol and PEG-3350 substitute the α- trehalose dehydrate and polysorbate-20, which are used as excipients in the EU-approved and US-licensed Herceptin formulations.
Study NCT06016387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a tumour-activated antineoplastic agent (antimetabolite). The molecular formula for capecitabine is C15H22FN3O6 and has a molecular weight of 359.35 g/mol.
Study NCT06016387 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain & Spinal Radiation
Description: Brain \& Spinal XRT is a treatment for patients with HER2+ metastatic breast cancer and leptomeningeal disease,
Study NCT06493227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No routine fibrinolysis inhibitors after surgery
Description: Tranexamic acid or epsilon-aminocaproic acid should be administered intravenously during surgery. The dosage and method of administration should be followed according to the routine practice of the participating site.
Study NCT06493227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine fibrinolysis inhibitors after surgery
Description: During surgery, it is recommended to administer 70% of the routine dose of Tranexamic acid or epsilon-aminocaproic acid intravenously. Following the surgery, the remaining 30% of this dose should be administered as a continuous intravenous infusion over the course of the first 4 hours.
Study NCT05729802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HoloSIM Software via Hololens 2
Description: Participants will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
Study NCT05729802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training by Mannequin Based Simulation
Description: Participants will train a via traditional mannequin based medical crisis scenario
Study NCT06131723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed tickler email
Description: The email notification from patients' PCP office will inform patients that a new review of their records shows they are due for an important medical exam. This intervention harnesses behavioral principles related to importance (medical exam described as important), personalization (records described as belonging to participants), urgency (participants are asked to sign in and make the recommended appointment as soon as possible), timeliness (participants are told that there has been a new review of their records), source effects and accountability (participants are told that a message from their PCP's office is waiting for their response). To make it easier for patients to find and review the MAP letter, the email also contains a link that directs patients to the MAP letter on their patient portal.
Study NCT05099679 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy (supportive counseling)
Description: Patients will complete a psychosocial intake that generally takes up to 2 hours, but the time required for the intake varies per patient. Subsequently they will be offered up to 7 optional counseling sessions with a clinical social worker
Study NCT05099679 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Cardiac Rehabilitation
Description: If eligible, patients will be referred to Movn Health Virtual Cardiac Rehabilitation to provide approximately 3 exercise sessions per week, with approximately eight coaching sessions over a 12 week period
Study NCT06463587 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to cladribine in two courses separated by 4 weeks.
Study NCT06463587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine Low Dose
Description: Participants will receive cladribine low dose in two courses separated by 4 weeks.
Study NCT06463587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cladribine Low Dose
Description: Participants will receive cladribine low dose in two courses separated by 4 weeks.
Study NCT06463587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine High Dose
Description: Participants will receive a total of cladribine high dose in two courses separated by 4 weeks.